Insulet (PODD) Stock Price, News & Analysis

15 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Insulet in the last twelve months. There are currently 3 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" PODD shares.
View PODD analyst ratings or view top-rated stocks.

15 analysts have issued 1-year price objectives for Insulet's shares. Their PODD share price targets range from $184.00 to $330.00. On average, they anticipate the company's share price to reach $243.21 in the next twelve months. This suggests a possible upside of 47.2% from the stock's current price.
View analysts price targets for PODD or view top-rated stocks among Wall Street analysts.

Insulet's stock was trading at $216.98 at the start of the year. Since then, PODD shares have decreased by 23.8% and is now trading at $165.25.
View the best growth stocks for 2024 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our PODD earnings forecast.

Insulet will be holding an earnings conference call on Thursday, May 9th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

Insulet Co. (NASDAQ:PODD) posted its quarterly earnings results on Thursday, February, 22nd. The medical instruments supplier reported $1.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.67 by $0.73. The medical instruments supplier earned $509.80 million during the quarter, compared to the consensus estimate of $461.26 million. Insulet had a net margin of 12.16% and a trailing twelve-month return on equity of 32.19%. The company's revenue was up 37.9% on a year-over-year basis. During the same period in the prior year, the company posted $0.55 earnings per share.

ETFs with the largest weight of Insulet (NASDAQ:PODD) stock in their portfolio include Fidelity Digital Health ETF (FDHT), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), Goldman Sachs Future Health Care Equity ETF (GDOC), Invesco Focused Discovery Growth ETF (IVDG), First Trust Indxx Medical Devices ETF (MDEV), Fidelity Disruptive Medicine ETF (FMED), Simplify Health Care ETF (PINK) and SPDR S&P Health Care Equipment ETF (XHE).

Insulet updated its first quarter 2024 earnings guidance on Thursday, February, 22nd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $419.0 million-$429.7 million, compared to the consensus revenue estimate of $442.5 million.

61 employees have rated Insulet Chief Executive Officer Shacey Petrovic on Glassdoor.com. Shacey Petrovic has an approval rating of 55% among the company's employees. This puts Shacey Petrovic in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Insulet investors own include NVIDIA (NVDA), DexCom (DXCM), Netflix (NFLX), Alibaba Group (BABA), Tesla (TSLA), Block (SQ), Walt Disney (DIS), Salesforce (CRM), Roku (ROKU) and Trade Desk (TTD).

Insulet's stock is owned by a number of retail and institutional investors. Top institutional investors include Los Angeles Capital Management LLC (0.43%), Portman Square Capital LLP (0.00%), Congress Asset Management Co. MA (0.06%), Banque Cantonale Vaudoise (0.01%), Diversified Trust Co (0.01%) and Moody National Bank Trust Division (0.00%). Insiders that own company stock include Bret Christensen, Charles Alpuche, Dan Manea, James Hollingshead, John A Fallon, Luciana Borio, Michael P Spears, Prem Singh, Sally Crawford, Shacey Petrovic and Wayde D Mcmillan.
View institutional ownership trends.

Shares of PODD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.